Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: Systematic review and meta-analyses

Addictive Behaviors

Volumn 39, Issue 3, 2014, Pages 520-531

  Goldner, Elliot M ^a   Lusted, Anna ^a   Roerecke, Michael ^b,c   Rehm, Jürgen ^b,c,d   Fischer, Benedikt ^a,b,c  

^a SIMON FRASER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Nonmedical prescription opioid use; Psychiatric disorder; Substance use treatment; Systematic review

Indexed keywords

OPIATE;

ANXIETY DISORDER; DEPRESSION; DRUG DEPENDENCE TREATMENT; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; OPIATE ADDICTION; PRESCRIPTION; PREVALENCE; PSYCHIATRIC DIAGNOSIS; QUALITY CONTROL; REVIEW; SUBSTANCE USE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

NONMEDICAL PRESCRIPTION OPIOID USE; PSYCHIATRIC DISORDER; SUBSTANCE USE TREATMENT; SYSTEMATIC REVIEW;

ANXIETY; ANXIETY DISORDERS; DEPRESSION; DEPRESSIVE DISORDER; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MENTAL DISORDERS; OPIOID-RELATED DISORDERS; PREVALENCE;

EID: 84891662527     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2013.11.022     Document Type: Review

References (112)

1. Abraham H.D., Fava M. Order of onset of substance abuse and depression in a sample of depressed outpatients. Comprehensive Psychiatry 1999, 40(1):44-50.
2. Alford D., Compton P., Samet J. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of Internal Medicine 2006, 144(2):127-134.
3. Amari E., Rehm J., Goldner E., Fischer B. Nonmedical prescription opioid use and mental health and pain comorbidities: A narrative review. Canadian Journal of Psychiatry 2011, 56(8):495-502.
4. Ballantyne J.C., Shin N.S. Efficacy of opioids for chronic pain: A review of the evidence. The Clinical Journal of Pain 2008, 24(6):469-478.
5. Banta-Green C., Maynard C., Koepsell T., Wells E., Donovan D. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction 2009, 104:775-783.
6. Barrett S., Meisner J., Stewart S. What constitutes prescription drug misuseα Problems and pitfalls of current conceptualizations. Current Drug Abuse Reviews 2008, 1(3):255-262.
7. Bellack A., Bennett M., Gearon J., Brown C., Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry 2006, 63(4):426-432.
8. Bibb J.L., Chambless D.L. Alcohol use and abuse among diagnosed agoraphobics. Behaviour Research and Therapy 1986, 24(1):49-58.
9. Blazer D.G., Kessler R., McGonagle K.A., Swartz M.S. The prevalence and distribution of major depression in a national community sample-The National Comorbidity Survey. American Journal of Psychiatry 1994, 151(7):979-986.
10. Boden J.M., Fergusson D.M. Alcohol and depression. Addiction 2011, 106(5):906-914.
11. Bohnert A.S.B., Valenstein M., Bair M.J., Ganoczy D., McCarthy J.F., Ilgen M.A., et al. Association between opioid prescribing patterns and opioid overdose-related deaths. The Journal of the American Medical Association 2011, 305(13):1315-1321.
12. Brady K., Sinha R. Co-occurring mental and substance use disorders: The neurobiological effects of chronic stress. American Journal of Psychiatry 2005, 162(8):1483-1493.
13. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence 2004, 73(2):199-207.
14. Campbell L.C., Clauw D.J., Keefe F.J. Persistent pain and depression: A biopsychosocial perspective. Biological Psychiatry 2003, 54(3):399-409.
15. Centers for Disease Control and Prevention (CDC) Vital signs: Overdoses of prescription opioid pain relievers-United States, 1999-2008. Morbidity and Mortality Weekly Report 2011, 60(43):1487-1492.
16. Chalmers T.C., Smith H.J., Blackburn B., Silverman B., Schroeder B., Reitman D., et al. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials 1981, 2(1):31-49.
17. Chen K.W., Banducci A.N., Guller L., Macatee R.J., Lavelle A., Daughters S.B., et al. An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program. Drug and Alcohol Dependence 2011, 118(2-3):92-99.
18. Cicero T.J., Lynskey M., Todorov A., Inciardi J.A., Surratt H.L. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain 2008, 139(1):127-135.
19. Cicero T.J., Surratt H.L., Kurtz S., Ellis M.S., Inciardi J.A. Patterns of prescription opioid abuse and comorbidity in an aging treatment population. Journal of Substance Abuse Treatment 2012, 42(1):87-89.
20. Degenhardt L., Hall W., Lynskey M. Alcohol, cannabis and tobacco use among Australians: A comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction 2001, 96(11):1603-1614.
21. Dersh J., Polatin P.B., Gatchel R.J. Chronic pain and psychopathology: Research findings and theoretical considerations. Psychosomatic Medicine 2002, 64(5):773-786.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clinical Trials 1986, 7(3):177-188.
23. Detsky A.S., Naylor C.D., O'Rourke K., McGeer A.J., L'Abbe K.A. Incorporating variations in the quality of individual randomized trials into meta-analysis. Journal of Clinical Epidemiology 1992, 45(3):255-265.
24. Deyo R.A., Mirza S.K., Turner J.A., Martin B.I. Overtreating chronic back pain: Time to back offα. Journal of the American Board of Family Medicine 2009, 22(1):62-68.
25. Drake R.E., O'Neal E.L., Wallach M.A. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment 2008, 34(1):123-138.
26. Duval S., Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56(2):455-463.
27. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997, 315(7109):629-634.
28. Falk D.E., Yi H., Hilton M.E. Age of onset and temporal sequencing of lifetime DSM-IV alcohol use disorders relative to comorbid mood and anxiety disorders. Drug and Alcohol Dependence 2008, 94(1):234-245.
29. Fergusson D., Boden J., Horwood L. Tests of causal links between alcohol abuse or dependence and major depression. Archives of General Psychiatry 2009, 66(3):260-266.
30. Ferrari A., Coccia C.P.R., Bertolini A., Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacological Research 2004, 50(6):551-559.
31. Fischer B., Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician 2012, 15(3 Suppl.):ES191-ES203.
32. Fischer B., Ialomiteanu A., Boak A., Adlaf E., Rehm J., Mann R. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug and Alcohol Review 2013, 32(3):276-287.
33. Fischer B., Jones W., Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiology and Drug Safety 2013, 22(4):438-442.
34. Fischer B., Lusted A., Roerecke M., Taylor B., Rehm J. The prevalence of mental health and pain symptoms in general population samples reporting non-medical use of prescription opioids: A systematic review and meta-analysis. Journal of Pain 2012, 13(11):1029-1044.
35. Fishbain D.A., Cole B., Lewis J., Rosomoff H.L., Rosomoff R.S. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviorsα A structured evidence-based review. Pain Medicine 2008, 9(4):444-459.
36. Franklin G.M., Mai J., Turner J., Sullivan M., Wickizer T., Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: Impact of the Washington state opioid dosing guideline. American Journal of Industrial Medicine 2012, 55(4):325-331.
37. Goldenbaum D.M., Christopher M., Gallagher R.M., Fishman S., Payne R., Joranson D., et al. Physicians charged with opioid analgesic-prescribing offenses. Pain Medicine 2008, 9(6):737-747.
38. Goldsmith R., Garlapati V. Behavioral interventions for dual-diagnosis patients. Psychiatric Clinics of North America 2004, 27(4):709-725.
39. Grant B., Hasin D., Chou S., Stinson F., Dawson D. Nicotine dependence and psychiatric disorders in the United States-Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry 2004, 61(11):1107-1115.
40. Green T.C., Grimes Serrano J.M., Licari A., Budman S.H., Butler S.F. Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug and Alcohol Dependence 2009, 103(1-2):65-73.
41. Greenland S., O'Rourke K. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics (Oxford, England) 2001, 2(4):463-471.
42. Gunderson E., Fiellin D.A. Office-based maintenance treatment for opioid dependence: How does it compare with traditional approachesα. CNS Drugs 2008, 22(2):99-111.
43. Gureje O. Psychiatric aspects of pain. Current Opinion in Psychiatry 2007, 20(1):42-46.
44. Harris K., Edlund M. Use of mental health care and substance abuse treatment among adults with co-occurring disorders. Psychiatric Services 2005, 56(8):954-959.
45. Hasin D., Stinson F., Ogburn E., Grant B. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States-Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry 2007, 64(7):830-842.
46. Hays L. A profile of OxyContin addiction. Journal of Addictive Diseases 2004, 23(4):1-9.
47. Herbison P., Hay-Smith J., Gillespie W.J. Adjustment of meta-analyses on the basis of quality scores should be abandoned. Journal of Clinical Epidemiology 2006, 59(12):1249-1256.
48. Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21(11):1539-1558.
49. Jane-Llopis E., Matytsina I. Mental health and alcohol, drugs and tobacco: A review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug and Alcohol Review 2006, 25(6):515-536.
50. Jones C.M., Mack K.A., Paulozzi L.J. Pharmaceutical overdose deaths, United States, 2010. The Journal of the American Medical Association 2013, 309(7):657-659.
51. Juurlink D.N., Dhalla I.A. Dependence and addiction during chronic opioid therapy. Journal of Medical Toxicology 2012, 8(4):393-399.
52. Katz N. Abuse-deterrent opioid formulations: Are they a pipe dreamα. Current Rheumatology Reports 2008, 10(1):11-18.
53. Kelly T.M., Daley D.C., Douaihy A.B. Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors 2012, 37(1):11-24.
54. Kenan K., Mack K., Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Medicine 2012, 6(2):e41-e47.
55. Kessler R. The epidemiology of dual diagnosis. Biological Psychiatry 2004, 56(10):730-737.
56. Kessler R., Chiu W.T., Demier O., Walters E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry 2005, 62(6):617-627.
57. Kessler R., Nelson C.B., McGonagle K., Edlund M., Frank R., Leaf P. The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. American Journal of Orthopsychiatry 1996, 66(1):17-31.
58. Kessler R., Petukhova M., Sampson N., Zaslavsky A., Merikangas K., Avenevoli S., et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the national comorbidity survey replication adolescent supplement. Archives of General Psychiatry 2012, 69(4):372-380.
59. Khantzian E.J. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry 1997, 4(5):231-244.
60. Koob G.F., Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science 1997, 278(5335):52-58.
61. Kuo P., Gardner C.O., Kendler K.S., Prescott C.A. The temporal relationship of the onsets of alcohol dependence and major depression: Using a genetically informative study design. Psychological Medicine 2006, 36(8):1153-1162.
62. Kushner M. Relationship between alcohol problems and anxiety disorders. American Journal of Psychiatry 1996, 153(1):139-140.
63. Langbehn D.R., Philibert R., Caspers K.M., Yucuis R., Cadoret R.J. Association of a D2S2944 allele with depression specifically among those with substance abuse or antisocial personality. Drug and Alcohol Dependence 2006, 83(1):33-41.
64. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R. Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review 2011, 30(3):236-245.
65. Lesage A., Vasiliadis H.M., Gagné M.A., Dudgeon S., Kasman N., Hay C. Prevalence of mental illnesses and related service utilization in Canada: An analysis of the Canadian community health survey 2006, Canadian Collaborative Mental Health Initiative, Mississauga, ON.
66. Lusted A., Roerecke M., Goldner E., Rehm F., Fischer B. Prevalence of pain among non-medical prescription opioid users in substance use treatment populations: Systematic review and meta-analysis. Pain Physician 2013, 16(6):E671-E684.
67. Manchikanti L., Helm S., Fellows B., Janata J., Pampati V., Grider J., et al. Opioid epidemic in the United States. Pain Physician 2012, 15(3 Suppl.):ES9-ES38.
68. Manchikanti L., Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008, 11(2 Suppl.):S63-S88.
69. Martins S.S., Fenton M.C., Keyes K.M., Blanco C., Zhu H., Storr C.L. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: Longitudinal evidence from the national epidemiologic study on alcohol and related conditions. Psychological Medicine 2012, 42(6):1261-1272.
70. McCabe S.E., West B.T., Teter C.J., Boyd C.J. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Archives of Pediatrics & Adolescent Medicine 2012, 166(9):797-802.
71. Mendelson J., Flower K., Pletcher M., Galloway G. Addiction to prescription opioids: Characteristics of the emerging epidemic and treatment with buprenorphine. Experimental & Clinical Psychopharmacology 2008, 16(5):435-441.
72. Messina N., Grella C. Childhood trauma and women's health outcomes in a California prison population. American Journal of Public Health 2006, 96(10):1842-1848.
73. Miller N., Greenfeld A. Patient characteristics and risk factors for development of dependence on hydrocodone and oxycodone. American Journal of Therapeutics 2004, 11(1):26-32.
74. Moher D., Pham B., Jones A., Cook D.J., Jadad A.R., Moher M., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysesα. Lancet 1998, 352(9128):609-613.
75. Novak S.P., Calvin S.L., Glasheen C., Edlund M.J. The epidemiology and treatment of prescription drug disorders in the United States. Psychiatric disorders-trends and developments 2011, 367-388. InTech, Rijeka. T. Uehara (Ed.).
76. Okie S. A flood of opioids, a rising tide of deaths. New England Journal of Medicine 2010, 363(21):1981-1985.
77. Passik S.D. Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clinic Proceedings 2009, 84(7):593-601.
78. Passik S.D., Hays L., Eisner N., Kirsh K.L. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. Journal of Pain and Palliative Care Pharmacotherapy 2006, 20(2):5-13.
79. Patten S.B., Wang J.L., Williams J.V.A., Currie S., Beck C.A., Maxwell C.J., et al. Descriptive epidemiology of major depression in Canada. Canadian Journal of Psychiatry 2006, 51(2):84-90.
80. Paulozzi L., Baldwin G., Franklin G., Kerlikowske R.G., Jones C.M., Ghiya N., et al. CDC grand rounds: Prescription drug overdoses-A U.S. epidemic. Morbidity and Mortality Weekly Report 2012, 61(1):1-13.
81. Peindl K.S., Mannelli P., Wu L.T., Patkar A.A. Trends in nonheroin opioid abuse admissions: 1992-2004. Journal of Opioid Management 2007, 3(4):215-223.
82. Rounsaville B.J. Treatment of cocaine dependence and depression. Biological Psychiatry 2004, 56(10):803-809.
83. Rush B.R., Urbanoski K., Bassani D., Castel S., Wild T. The epidemiology of co-occurring substance use and the other mental disorders in Canada: Prevalence, service use and other mental disorders in Canada: Prevalence, service use and unmet needs. Mental disorder in Canada: An epidemiological perspective 2008, University of Toronto Press, Toronto. J. Cairney, D. Streiner (Eds.).
84. Sander H., Hays L. Prescription opioid dependence and treatment with methadone in pregnancy. Journal of Opioid Management 2005, 1(2):91-97.
85. Savage S.R. Assessment for addiction in pain-treatment settings. The Clinical Journal of Pain 2002, 18(4 Suppl.):S28-S38.
86. Smetanin P., Stiff D., Briante C., Adair C.E., Ahmad S., Khan M. The life and economic impact of major mental illnesses in Canada: 2011 to 2041 2011, RiskAnalytica, on behalf of the Mental Health Commission of Canada, Toronto, ON.
87. Sproule B., Brands B., Li S., Catz-Biro L. Changing patterns in opioid addiction: Characterizing users of oxycodone and other opioids. Canadian Family Physician 2009, 55(1):68-69.
88. Stanos S.P., Bruckenthal P., Barkin R.L. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: Potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proceedings 2012, 87(7):683-694.
89. StataCorp Stata statistical software: Release 11 2009, Stata Corporation LP, College Station, TX.
90. Sterne J.A.C., Schmid C.H., Tetzlaff J., Deeks J.J., Peters J., Macaskill P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal 2011, 343:d4002.
91. Strain E.C. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. The Clinical Journal of Pain 2002, 18(4 Suppl.):S14-S27.
92. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Journal of the American Medical Association 2000, 283(15):2008-2012.
93. Subramaniam G.A., Stitzer M.A. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug and Alcohol Dependence 2009, 101(1-2):13-19.
94. Substance Abuse and Mental Health Services Administration (SAMHSA) Results from the 2011 national survey on drug use and health: Detailed tables Retrieved November 25, 2012, from. http://www.samhsa.gov/data/NSDUH/2011SummNatFindDetTables/NSDUH-DetTabsPDFWHTML2011/2k11DetailedTabs/Web/HTML/NSDUH-DetTabsLOTSect1pe2011.htm#TopOfPage.
95. Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment episode data set (TEDS) 2000-2010 national admissions for substance abuse treatment services. DASIS Series S-61, HHS Publication No. (SMA) 12-4701 2012, Substance Abuse and Mental Health Services Administration, Rockville, MD.
96. Sullivan M.D., Edlund M.J., Steffick D., Unutzer J. Regular use of prescribed opioids: Association with common psychiatric disorders. Pain 2005, 119(1-3):95-103.
97. Thomas S.E., Randall C.L., Carrigan M.H. Drinking to cope in socially anxious individuals: A controlled study. Alcoholism, Clinical and Experimental Research 2003, 27(12):1937-1943.
98. Toblin R., Paulozzi L., Logan J., Hall A., Kaplan J. Mental illness and psychotropic drug use among prescription drug overdose deaths: A medical examiner chart review. Journal of Clinical Psychiatry 2010, 71(4):491-496.
99. Turk D.C., Swanson K.S., Gatchel R.J. Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. Clinical Journal of Pain 2008, 24(6):497-508.
100. Veilleux J.C., Colvin P.J., Anderson J., York C., Heinz A.J. A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clinical Psychology Review 2010, 30(2):155-166.
101. Volkow N.D., McLellan T.A., Cotto J.H., Karithanom M., Weiss S.R. Characteristics of opioid prescriptions in 2009. The Journal of the American Medical Association 2011, 305(13):1299-1301.
102. Wachholtz A., Ziedonis D., Gonzalez G. Comorbid pain and opioid addiction: Psychosocial and pharmacological treatments. Substance Use & Misuse 2011, 46(12):1536-1552.
103. Wang J., Patten S.B. A prospective study of sex-specific effects of major depression on alcohol consumption. Canadian Journal of Psychiatry 2001, 46(5):422-425.
104. Wasan A.D., Butler S.F., Budman S.H., Fernandez K., Weiss R.D., Greenfield S.F., et al. Does report of craving opioid medication predict aberrant drug behaviour among chronic pain patientsα. Clinical Journal of Pain 2009, 25(3):193-198.
105. Weaver M., Schnoll M.D. Abuse liability in opioid therapy for pain treatment in patients with an addiction history. The Clinical Journal of Pain 2002, 18(4 Suppl.):S61-S69.
106. Weiss F., Markou A., Lorang M.T., Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Research 1992, 593(2):314-318.
107. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry 2011, 68(12):1238-1246.
108. WHO International Consortium in Psychiatric Epidemiology Cross-national comparisons of the prevalences and correlates of mental disorders. Bulletin of the World Health Organization 2000, 78(4):413-426.
109. Wiech K., Ploner M., Tracey I. Neurocognitive aspects of pain perception. Trends in Cognitive Sciences 2008, 12(8):306-313.
110. Wiedemer N.L., Harden P.S., Arndt I.O., Gallagher R.M. The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine 2007, 8(7):573-584.
111. Wisniewski A.M., Purdy C.H., Blondell R.D. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. Journal of Addictive Diseases 2008, 27(1):1-11.
112. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug and Alcohol Dependence 2003, 69(3):215-232.